Bayer's radiotherapy Xofigo wins FDA nod in prostate cancer

The FDA has hit the green light for Xofigo--initially called Alpharadin or radium-223 chloride--for castration-resistant prostate cancer. The approval demonstrates the agency's growing comfort with targeted cancer therapies that arrive at its doorstep with compelling overall survival benefits. The approval comes just three months after the FDA granted priority review status to the radiopharmaceutical therapy, from Bayer and Norway's Algeta. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.